About this item:

72 Views | 33 Downloads

Author Notes:

Alicia Morgans, aliciak_morgans@dcfi.harvard.edu

Anju Nohria, anohria@bwh.harvard.edu

Melissa Y.Y. Moey: Conceptualization, Investigation, Writing – original draft, Writing – review & editing, Visualization. Cassandra Hennessy: Methodology, Validation, Formal analysis, Data curation, Writing – review & editing. Benjamin French: Project administration, Methodology, Validation, Formal analysis, Data curation, Writing – review & editing. Jeremy L. Warner: Project administration, Methodology, Validation, Formal analysis, Data curation, Writing – review & editing. Matthew D. Tucker: Data curation, Writing – review & editing. Daniel J. Hausrath: Data curation, Writing – review & editing. Dimpy P. Shah: Data curation, Writing – review & editing. Jeanne M. DeCara: Data curation, Writing – review & editing. Ziad Bakouny: Data curation, Writing – review & editing. Chris Labaki: Data curation, Writing – review & editing. Toni K. Choueiri: Project administration, Resources, Data curation, Writing – review & editing. Susan Dent: Data curation, Writing – review & editing. Nausheen Akhter: Data curation, Writing – review & editing. Roohi Ismail-Khan: Data curation, Writing – review & editing. Lisa Tachiki: Data curation, Writing – review & editing. David Slosky: Data curation, Writing – review & editing. Tamar S. Polonsky: Data curation, Writing – review & editing. Joy A. Awosika: Data curation, Writing – review & editing. Audrey Crago: Data curation, Writing – review & editing. Trisha Wise-Draper: Data curation, Writing – review & editing. Nino Balanchivadze: Data curation, Writing – review & editing. Clara Hwang: Data curation, Writing – review & editing. Leslie A. Fecher: Data curation, Writing – review & editing. Cyndi Gonzalez Gomez: Data curation, Writing – review & editing. Brandon Hayes-Lattin: Data curation, Writing – review & editing. Michael J. Glover: Data curation, Writing – review & editing. Sumit A. Shah: Data curation, Writing – review & editing. Dharmesh Gopalakrishnan: Data curation, Writing – review & editing. Elizabeth A. Griffiths: Data curation, Writing – review & editing. Daniel H. Kwon: Data curation, Writing – review & editing. Vadim S. Koshkin: Data curation, Writing – review & editing. Sana Mahmood: Data curation, Writing – review & editing. Babar Bashir: Data curation, Writing – review & editing. Taylor Nonato: Data curation, Writing – review & editing. Pedram Razavi: Data curation, Writing – review & editing. Rana R. McKay: Data curation, Writing – review & editing. Gayathri Nagaraj: Data curation, Writing – review & editing. Eric Oligino: Data curation, Writing – review & editing. Matthew Puc: Data curation, Writing – review & editing. Polina Tregubenko: Data curation, Writing – review & editing. Elizabeth M. Wulff-Burchfield: Data curation, Writing – review & editing. Zhuoer Xie: Data curation, Writing – review & editing. Thorvardur R. Halfdanarson: Data curation, Writing – review & editing. Dimitrios Farmakiotis: Data curation, Writing – review & editing. Elizabeth J. Klein: Data curation, Writing – review & editing. Elizabeth V. Robilotti: Data curation, Writing – review & editing. Gregory J. Riely: Data curation, Writing – review & editing. Jean-Bernard Durand: Data curation, Writing – review & editing. Salim S. Hayek: Data curation, Writing – review & editing. Lavanya Kondapalli: Data curation, Writing – review & editing. Stephanie Berg: Data curation, Writing – review & editing. Timothy E. O'Connor: Data curation, Writing – review & editing. Mehmet A. Bilen: Data curation, Writing – review & editing. Cecilia Castellano: Data curation, Writing – review & editing. Melissa K. Accordino: Data curation, Writing – review & editing. Blau Sibel: Data curation, Writing – review & editing. Lisa B. Weissmann: Data curation, Writing – review & editing. Chinmay Jani: Data curation, Writing – review & editing. Daniel B. Flora: Data curation, Writing – review & editing. Lawrence Rudski: Data curation, Writing – review & editing. Miriam Santos Dutra: Data curation, Writing – review & editing. Bouganim Nathaniel: Data curation, Writing – review & editing. Erika Ruíz-García: Data curation, Writing – review & editing. Diana Vilar-Compte: Data curation, Writing – review & editing. Shilpa Gupta: Data curation, Writing – review & editing. Alicia Morgans: Conceptualization, Methodology, Investigation, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision. Anju Nohria: Conceptualization, Methodology, Investigation, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision.

We thank all members of the CCC19 steering committee: Toni K. Choueiri, Narjust Duma, Dimitrios Farmakiotis, Petros Grivas, Gilberto de Lima Lopes Jr, Corrie A. Painter, Solange Peters, Brian I. Rini, Dimpy P. Shah, Michael A. Thompson, and Jeremy L. Warner, for their invaluable guidance of the CCC19.

R.M reports research funding from Bayer, Pfizer, and Tempus; and 18 personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, 19 Caris, Dendreon, Exelixis, Janssen, Johnson and Johnson, Merck & Co, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, Tempus, and Vividion. A.N. reports consulting fees from AstraZeneca, Takeda Oncology and Bantam Pharmaceuticals. B.B. reports research support to institution from Amgen, Bicycle Therapeutics, Boehringer Ingelheim, Ikena Oncology, Kahr Medical, Merck, Syros, Tarveda Therapeutics. Z.B. receives research support from Genentech/imCORE and Bristol Myers Squibb. Personal fees from UpToDate. L.A.F reports clinical trial funding from BMS, EMDserono, Pfizer, Merck, Array, Kartos, Incyte, personal fees from Elsevier, ViaOncology, outside the submitted work. J.L.W. reports research funding from NIH/NCI during the conduct of the work, research funding from AACR, consulting fees from Westat, Roche, Flatiron Health, Melax Tech, other from HemOnc.org LLC (ownership), outside the submitted work. C.H reports stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck, all outside the submitted work. The remaining authors have nothing to disclose.

Subjects:

Research Funding:

This work was supported by National Cancer Institute (NCI) grant P30CA016056 involving the use of Roswell Park Comprehensive Cancer Center's Hematologic Procurement Shared Resource and grant P30 CA123456. This study was also supported by grants from the National Cancer Institute grant number P30 CA068485 to Vanderbilt University Medical Center. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS / NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • COVID-19 outcomes
  • Cardio-oncology
  • Cardiovascular disease
  • Cancer

COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

Show all authors Show less authors

Tools:

Journal Title:

TRANSLATIONAL ONCOLOGY

Volume:

Volume 34

Publisher:

, Pages 101709-101709

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. Objectives: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. Methods: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. Results: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54–74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11–1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p<0.001). CVD/CVRF was associated with worse COVID-19 severity in patients who had not received recent cancer therapy, but not in those undergoing active cancer therapy (OR 1.51 [95% CI 1.31–1.74] vs. OR 1.04 [95% CI 0.90–1.20], pinteraction <0.001). Conclusions: Co-morbid CVD/CVRF is associated with higher COVID-19 severity among patients with cancer, particularly those not receiving active cancer therapy. While infrequent, COVID-19 related CV complications were higher in patients with comorbid CVD/CVRF. (COVID-19 and Cancer Consortium Registry [CCC19]; NCT04354701).

Copyright information:

© 2023 Published by Elsevier Inc.

Export to EndNote